前列腺癌藥物市場：按藥物類型、通路和地區分類

Prostate Cancer Therapeutics Market, By Drug Type, By Distribution Channel, By Geography

出版日期: 2026年05月22日 | 出版商:

Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026年前列腺癌治療市場規模估計為222億美元，預計2033年將達到293億美元。預計2026年至2033年，該市場將以8.1%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	222億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	8.10%	2033年市場規模預測：	293億美元

攝護腺癌是老年男性最常見的癌症。它是一項重要的健康問題，尤其是在已開發國家，老年男性的發生率很高。根據歐洲泌尿系統協會 (EAU) 2016 年的報告，北歐和西歐的發生率最高（70 歲以上男性每 10 萬例超過 200 例），而東歐和南歐的發生率也持續上升。因此，亟需為前列腺癌患者引進創新藥物，以滿足未被滿足的醫療需求並取得令人滿意的療效。目前，轉移性去勢抗性前列腺癌 (CRPC) 的典型治療方法是化療（多西他賽、Cabazitaxel）或二線荷爾蒙療法，例如Abiraterone或曲普瑞林。對於無症狀或輕度轉移性 CRPC 且無內臟轉移的患者，可採用免疫療法，例如 SiprEthel-T。

市場動態

由於研究機構和大學持續投資研發針對這些腫瘤的治療方法，市場展現出強勁的成長動能。目前，新治療方法主要核准用於去勢抗性腫瘤患者，預計將與現有治療方法（如Zytiga、Extandi和非專利他賽學名藥）競爭或作為其輔助性治療治療手段。一些前景可觀的在研產品正處於二期治療方法，例如二甲雙胍（曼蘇拉大學）、 Avelumab（杜克大學醫學中心）和LY2452473（丹娜-法伯研發線產品研究所），預計將在不久的將來上市。然而，這些藥物的高成本和副作用可能會抑制市場成長。

本研究的主要特點：

本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和核准、區域前景以及主要參與者採取的競爭策略。
本研究根據以下參數對全球前列腺癌治療市場的主要參與者進行了分析：公司概況、財務表現、產品系列、地理分佈、分銷策略、關鍵發展和策略以及未來計劃。
透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、加強分銷管道、市場擴張和行銷策略做出明智的決策。
這份全球前列腺癌治療市場報告旨在為行業內的各類相關人員提供參考，包括投資者、產品製造商、經銷商、供應商、研究和諮詢公司、新參與企業和金融分析師。
在分析前列腺癌藥物市場時使用的各種策略矩陣相關人員提供了關鍵訊息，以便他們做出適當的策略決策。

北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 日本
- 印度
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
拉丁美洲
- 巴西
- 墨西哥
- 其他拉丁美洲國家
非洲
- 北非
- 中非
- 南非
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家

第7章競爭情勢

熱圖分析
公司簡介
- Johnson & Johnson
- Astellas Pharma, Inc
- Sanofi
- Bayer AG
- AstraZeneca Plc
- Pfizer, Inc.
- Dendreon Corporation（Sanpower Group Co. Ltd.）
- Ipsen Group
- Tolmar Inc
- Endo International plc
- AbbVie, Inc.

第8章

分析師意見
調查方法

簡介目錄

Product Code: CMI1257

Prostate Cancer Therapeutics Market is estimated to be valued at USD 22.2 Bn in 2026 and is expected to reach USD 29.3 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.1% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 22.2 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	8.10%	2033 Value Projection:	USD 29.3 Bn

Prostate cancer is the most common cancer among the geriatric male population. It is a major health concern, especially in developed countries with a greater proportion of elderly men being affected by it. According to European Association of Urology, 2016, the incidence is highest in Northern and Western Europe (> 200 per 100,000 men with age group > 70 years of age), while rates in Eastern and Southern Europe have showed a continuous increase. Thus, the introduction of innovative drugs for patients with prostate cancer is required to meet the unmet needs with satisfactory results. Currently, metastatic castration-resistant prostate cancer (CRPC) is usually treated with chemotherapy (docetaxel, and cabazitaxel) or secondary hormonal therapeutic agents such as abiraterone or Triptorelin. Immunotherapy with Sipuleucel-T is prescribed in treating asymptomatic or minimally metastatic CRPC without visceral metastasis.

Market Dynamics

The market is gaining significant traction due to continuous investment by research organizations and universities for the development of therapeutic products for the treatment of such tumors. Novel therapies are expected to be predominately approved in castration-resistant patients, and to compete with better-established treatments, such as Zytiga, Xtandi and generic docetaxel, or to act as adjuvants to established therapies. For instance, there is a strong pipeline of products such as Metformin (Mansoura University), Avelumab (Duke University Medical Center), LY2452473 (Dana-Farber Cancer Institute), which are in their phase 2 studies and are projected to enter the market in the near future. However, high cost and side effects associated with drugs can restraint the market growth.

Key features of the study:

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global prostate cancer therapeutics market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
Key companies covered as a part of this study include Johnson & Johnson, Astella, Inc, Sanofi-Aventis, Bayer AG, AstraZeneca Plc, Pfizer Inc., Dendreon Corporation (Sanpower Group Co. Ltd.), Ipsen Group, Tolmar Inc, Endo Pharmaceuticals, AbbVie, Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, distribution channel upgrades, market expansion and marketing tactics.
The global prostate cancer therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for prostate cancer therapeutics market, research and consulting firms, new entrants and financial analysts
Various strategy matrices used in analyzing the prostate cancer therapeutics market would provide stakeholders vital inputs to make strategic decisions accordingly

Market Segmentation

By Drug Type (Revenue, USD Bn, 2021-2033)
- Hormonal Therapy
- Anti-androgens
- Immunotherapy
- Targeted Therapy
- Chemotherapy
By Distribution Channel (Revenue, USD Bn, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Key Players
- Johnson & Johnson
- Astella, Inc
- Sanofi-Aventis
- Bayer AG
- AstraZeneca Plc
- Pfizer Inc.
- Dendreon Corporation (Sanpower Group Co. Ltd.)
- Ipsen Group
- Tolmar Inc
- Endo Pharmaceuticals
- AbbVie, Inc.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Regulatory Scenario
Reimbursement Scenario
Pipeline Analysis
PEST Analysis
PORTER'S Five Forces

4. Global Prostate Cancer Therapeutics Market, By Drug Type, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hormonal Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Anti-Androgens
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Targeted Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

5. Global Prostate Cancer Therapeutics Market, By Distribution Channel, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

6. Global Prostate Cancer Therapeutics Market, By Region, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, By Region, 2022-2033
North America
- Market Size and Forecast, By Drug Type, 2021-2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, By Country, 2021-2033, (USD Bn)
  - U.S.
  - Canada
Europe
- Market Size and Forecast, By Drug Type, 2021-2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, By Country, 2021-2033, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug Type, 2021-2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, By Country, 2021-2033, (USD Bn)
  - China
  - Japan
  - India
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Market Size and Forecast, By Drug Type, 2021-2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, By Country, 2021-2033, (USD Bn)
  - Brazil
  - Mexico
  - Rest of Latin America
Africa
- Market Size and Forecast, By Drug Type, 2021-2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, By Country, 2021-2033, (USD Bn)
  - Northern Africa
  - Central Africa
  - South Africa
Middle East
- Market Size and Forecast, By Drug Type, 2021-2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, By Country, 2021-2033, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East

7. Competitive Landscape

Heat Map Analysis
Company Profiles
- Johnson & Johnson
  - Company Overview
  - Technology Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Astellas Pharma, Inc
  - Company Overview
  - Technology Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Sanofi
  - Company Overview
  - Technology Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Bayer AG
  - Company Overview
  - Technology Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- AstraZeneca Plc
  - Company Overview
  - Technology Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Pfizer, Inc.
  - Company Overview
  - Technology Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Dendreon Corporation (Sanpower Group Co. Ltd.)
  - Company Overview
  - Technology Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Ipsen Group
  - Company Overview
  - Technology Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Tolmar Inc
  - Company Overview
  - Technology Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Endo International plc
  - Company Overview
  - Technology Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- AbbVie, Inc.
  - Company Overview
  - Technology Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies